Skip to main content
. 2019 Jan 13;196(1):86–96. doi: 10.1111/cei.13254

Table 3.

Levels and prevalence of antibody responses against MSPs

Patients No. MSP1p19 MSP4p40 MSP4p30 MSP4p20 MSP2 MSP3 MSP5
Mean1 Prev2 Mean Prev Mean Prev Mean Prev Mean Prev Mean Prev Mean Prev
All severe 110 7·8 81% 6·1 65% 8·4 73% 5·5 67% 3·3 59% 2·0 26% 3·7 66%
MM 91 6·5 53% 4·9 45% 4·5 40% 4·0 41% 3·0 32% 2·0 18% 2·6 33%
Comp. CM versus MM3 P = 0.16 < 10–3 0·12 < 10–2 < 10–3 < 10–4 0·01 < 10–3 0·13 < 10–4 0·4 0·17 < 10–3 < 10–4
survival 83 8·3 87% 6·4 70% 8·7 77% 5·8 71% 3·4 64% 2·2 33% 3·8 71%
fatal cases 27 6·2 63% 5·3 52% 7·4 59% 4·5 56% 2·7 44% 1·6 7% 3·6 52%
Comp. surv versus fatal3 P = 0.05 0·01 0·23 0·93 0·24 0·08 0·1 0·16 0·09 0·11 0·01 0·01 0·89 0·09
1

Mean and maximum (Max) levels antibody responses to merozoite antigen expressed in optical density (OD) ratio.

2

Prevalence (Prev) of positive antibody responses, i.e. individuals with OD ratio > 2.

3

Comparison of antibody levels (Mann–Whitney test) and prevalence of responders (Fisher's exact test). MSP = merozoite surface proteins; CM = cerebral malaria; MM = mild malaria.